MDAI vs. STIM, SGHT, ECOR, ZJYL, LNSR, PDEX, TELA, NSPR, EDAP, and FONR
Should you be buying Spectral AI stock or one of its competitors? The main competitors of Spectral AI include Neuronetics (STIM), Sight Sciences (SGHT), electroCore (ECOR), Jin Medical International (ZJYL), LENSAR (LNSR), Pro-Dex (PDEX), TELA Bio (TELA), InspireMD (NSPR), Edap Tms (EDAP), and FONAR (FONR). These companies are all part of the "medical equipment" industry.
Spectral AI vs.
Spectral AI (NASDAQ:MDAI) and Neuronetics (NASDAQ:STIM) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, community ranking, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends.
Spectral AI currently has a consensus target price of $4.75, suggesting a potential upside of 219.01%. Neuronetics has a consensus target price of $4.67, suggesting a potential downside of 5.44%. Given Spectral AI's stronger consensus rating and higher probable upside, equities analysts clearly believe Spectral AI is more favorable than Neuronetics.
In the previous week, Neuronetics had 11 more articles in the media than Spectral AI. MarketBeat recorded 12 mentions for Neuronetics and 1 mentions for Spectral AI. Spectral AI's average media sentiment score of 0.94 beat Neuronetics' score of 0.22 indicating that Spectral AI is being referred to more favorably in the media.
Spectral AI has a beta of 0.43, suggesting that its stock price is 57% less volatile than the S&P 500. Comparatively, Neuronetics has a beta of 2.17, suggesting that its stock price is 117% more volatile than the S&P 500.
Spectral AI has higher earnings, but lower revenue than Neuronetics. Neuronetics is trading at a lower price-to-earnings ratio than Spectral AI, indicating that it is currently the more affordable of the two stocks.
Spectral AI has a net margin of -40.78% compared to Neuronetics' net margin of -50.09%. Spectral AI's return on equity of 0.00% beat Neuronetics' return on equity.
67.1% of Spectral AI shares are owned by institutional investors. Comparatively, 53.6% of Neuronetics shares are owned by institutional investors. 56.7% of Spectral AI shares are owned by insiders. Comparatively, 9.8% of Neuronetics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Neuronetics received 123 more outperform votes than Spectral AI when rated by MarketBeat users. However, 100.00% of users gave Spectral AI an outperform vote while only 68.45% of users gave Neuronetics an outperform vote.
Summary
Spectral AI beats Neuronetics on 12 of the 19 factors compared between the two stocks.
Get Spectral AI News Delivered to You Automatically
Sign up to receive the latest news and ratings for MDAI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Spectral AI Competitors List
Related Companies and Tools
This page (NASDAQ:MDAI) was last updated on 3/4/2025 by MarketBeat.com Staff
Free MDAI Stock Alerts